Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2017

View Archived Issues

Florida Department of Health awards grant for gp96-based Zika vaccine development

DSMB recommends continuation of phase III trial of apabetalone

New phase III outcomes program for empagliflozin in chronic heart failure

Kisqali available for U.S. order through Biologics

Efficacy seen with CLS-003 digoxin/furosemide patch in treating cutaneous warts

Biosceptre obtains conditional ethics committee approval for phase I trial of BIL-03s

Phase II results for macitentan presented for pulmonary hypertension

Ergomed initiates European phase IIb study of PeproStat

Achillion Pharmaceuticals describes novel complement factor D inhibitors

Gachon University, Bio-Medical Science and Yoo Young Pharm patent mTOR inhibitors

Umecrine Cognition initiates phase Ib/IIa study of GR-3027 for hepatic encephalopathy

Yang Ji Chemical Co. and Han Wha Pharma Co. describe new JAK inhibitors

Sunshine Lake Pharma patents cathepsin K inhibitors

Abbvie discloses new sphingosine 1-phosphate receptor 5 modulators

Janssen-Cilag conducts oral bioavailability trial of JNJ-63623872/oseltamivir phosphate

Saniona updates plans for phase IIa study of Tesomet in Prader-Willi syndrome

AB Science's phase II/III trial of masitinib in ALS meets primary endpoint

Ipsen returns LRRK2-based research program in Parkinson's to Oncodesign

Japanese collaborators announce open innovation research on new cancer immunotherapy

Study suggests PARP-1 is a therapeutic target for treating Merkel cell carcinoma

CBT Pharmaceuticals begins phase I study of CBT-501 in advanced, relapsed or recurrent solid tumors

MDR3 and MRP1 found as poor prognostic markers in Wilm's tumor after SIOP-93-01 treatment protocol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...